Biosimilars show comparable safety with Humira among new users with psoriasis in a multinational cohort study, but ...

The request is based on findings from the Phase III ASTRO study, which achieved the primary endpoint of clinical remission at ...

MoonLake Immunotherapeutics' shares have dipped recently, with a catalyst vacuum until mid-2025 when pivotal trial data for ...

Here's how this drugmaker proved the bears wrong, and why that means it's worth investing $1,500 in today. Read More: Earn up ...

At the start of 2023, U.S. patent exclusivity expired for the blockbuster drug Humira, AbbVie's chief cash ... arthritis to Crohn's disease to plaque psoriasis. Now, biosimilar generic versions ...

Whether you’re looking for a psoriasis treatment with fewer side effects than your current therapy or it affects your daily life, you may want to switch to a biologic. Speaking with your doctor ...

In contrast, Skyrizi saw a 50.8% global increase to $3.205 billion, and Rinvoq rose 45.3% to $1.614 billion. Products such as Humira, Skyrizi, and Rinvoq are used to treat plaque psoriasis, ankylosing ...

In contrast, Skyrizi saw a 50.8% global increase to $3.205 billion, and Rinvoq rose 45.3% to $1.614 billion. Products like Humira, Skyrizi, and Rinvoq are used to treat plaque psoriasis, ankylosing ...